Raffaele Colombo, Associate Director, Medicinal Chemistry at Zymeworks Inc., posted on X:
“The tyranny of PBD ADCs: ADCT-602 has been discontinued!
My take for AACR25 educational session
Read more about ADC payload potency and MTD in our recent review, or in our Cancer Cell commentary.”
Title: The therapeutic window of antibody drug conjugates: A dogma in need of revision
Authors: Raffaele Colombo, Jamie R. Rich
Read The Full Article at Cancer Cell.
More posts featuring Raffaele Colombo.